ETX101

Small molecule

EEncoded Therapeutics

ETX101 is one of 13 small molecule programs targeting Dravet syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dravet SyndromeActive, not recruiting

Dravet SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Dravet Syndrome

#DrugCompanyPhaseTrials

Sympazan

Lundbeck

Phase 3

2 2

Epidiolex

Jazz Pharmaceuticals

Phase 3

2 3

Lorcaserin

Eisai

Phase 3

2 4

Soticlestat

Takeda

Phase 3

1 5

Calan

VVal Adams

Phase 2

1 6

Translarna

PPTC Therapeutics

Phase 2

1 7

GWP42003-P

Jazz Pharmaceuticals

Phase 2

3 8

Clemizole Hcl

EEpygenix

Phase 3

1 9

LP352

LLongboard Pharmaceuticals

Phase 3

1 10

Zorevunersen

SStoke Therapeutics, Inc

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1/2Active, not recruiting

Dravet Syndrome

NCT06112275

Q4 2030

Phase 1/2Active, not recruiting

Dravet Syndrome

NCT06283212

Q1 2033

PreclinicalRecruiting

Dravet Syndrome

NCT05419492

Clinical

Trials by Indication[1]

Dravet syndrome3 trials

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Active, not recruiting·EEncoded Therapeutics·Phase 1/2·NCT06112275·4 enrolled

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

Active, not recruiting·EEncoded Therapeutics·Phase 1/2·NCT06283212·5 enrolled

ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome

Recruiting·EEncoded Therapeutics·Preclinical·NCT05419492·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ETX101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ETX101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ETX101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Encoded Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EEncoded Therapeutics

ETX101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q4 2030

Q1 2033

Trials by Indication[1]

Dravet syndrome3 trials

References

Drug Info

Quick Facts

Related News